poisar

Stocks · News reference

8-K filing — LifeMD, Inc. (LFMDP)

Aug 5, 2026, 8:10 PMSEC EDGAR

Filed: 2026-08-05 AccNo: 0001493152-26-036170 Size: 13 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LFMDP
Source
edgar
Observed
Aug 5, 2026, 8:10 PM
Checked
Aug 5, 2026, 8:10 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Jun 22, 2026, 12:00 PMLifemd, Inc.

    LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

    LifeMD announced an exclusive co-marketing collaboration with Halozyme's subsidiary Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, an FDA-approved testosterone auto-injector. The program will launch in July 2026 across 37 states, offering patients virtual clinical evaluation, lab testing, and home delivery of medication at a transparent price of approximately $249 per month, addressing barriers to hypogonadism treatment.

    Read original at globenewswire-inc
    LFMDLFMDPHALO